Acasti Pharma (ACST)
(Delayed Data from NSDQ)
$3.33 USD
+0.05 (1.47%)
Updated Oct 18, 2024 03:56 PM ET
After-Market: $3.30 -0.03 (-0.90%) 5:44 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Acasti Pharma, Inc. [ACST]
Reports for Purchase
Showing records 1 - 20 ( 44 total )
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
STRIVE-ON GTX-104 Pivotal Safety Trial 50% Enrolled
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
KOL Bolsters View on Strong GTX-104 Prospects; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
Company Now Entirely Focused on GTX-104, With FDA Nod to Start Pivotal Safety Trial in 4Q; Reiterate Buy; Target to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
Pipeline Passing PK Prerequisites; Next Up is Key FDA GTX-104 Pathway Blessing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
Underappreciated Drug-Delivery Play Targeting Orphan Opportunities; Initiate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
Upcoming TRILOGY 2 Top Line Could Offer CaPre Hope; Results Expected Late August 2020
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
TRILOGY 1 Update Reflects Favorably On CaPre?s Triglyceride-Lowering Activity, While Raising New Issues On Study Design
Provider: Echelon Welath Partners
Analyst: LOE D
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
FQ320 Update Affirms Timelines To TRILOGY 1 - 2 Updates - Insight Into TRILOGY 1 Underperformance Still Pending
Provider: Echelon Welath Partners
Analyst: LOE D
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
TRILOGY Trial Clarity on Horizon, As Explanation of Observed Placebo Effect Remains Forthcoming; Reducing PT to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
CaPre Misses Key TRILOGY 1 Endpoint, But Due To Unusual Control Data - Not CaPre?s Own Lipid-Lowering Pharmacology
Provider: Echelon Welath Partners
Analyst: LOE D